|
1
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Myers SH, Brunton VG and Unciti-Broceta A:
AXL inhibitors in cancer: A medicinal chemistry perspective. J Med
Chem. 59:3593–3608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graham DK, DeRyckere D, Davies KD and Earp
HS: The TAM family: Phosphatidylserine sensing receptor tyrosine
kinases gone awry in cancer. Nat Rev Cancer. 14:769–785. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holland SJ, Pan A, Franci C, Hu Y, Chang
B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a
selective small molecule inhibitor of Axl kinase, blocks tumor
spread and prolongs survival in models of metastatic breast cancer.
Cancer Res. 70:1544–1554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sheridan C: First Axl inhibitor enters
clinical trials. Nat Biotechnol. 31:775–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koorstra JB, Karikari CA, Feldmann G,
Bisht S, Rojas PL, Offerhaus GJ, Alvarez H and Maitra A: The Axl
receptor tyrosine kinase confers an adverse prognostic influence in
pancreatic cancer and represents a new therapeutic target. Cancer
Biol Ther. 8:618–626. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo
SS, Lui WY and Lin WC: Clinical significance of AXL kinase family
in gastric cancer. Anticancer Res. 22:1071–1080. 2012.
|
|
10
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Konieczkowski DJ, Johannessen CM,
Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT,
Barzily-Rokni M, Straussman R, Haq R, et al: A melanoma cell state
distinction influences sensitivity to MAPK pathway inhibitors.
Cancer Discov. 4:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong J, Peng D, Chen Z, Sehdev V and
Belkhiri A: ABL regulation by AXL promotes cisplatin resistance in
esophageal cancer. Cancer Res. 73:331–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hong CC, Lay JD, Huang JS, Cheng AL, Tang
JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is
induced by chemotherapy drugs and overexpression of AXL confers
drug resistance in acute myeloid leukemia. Cancer Lett.
268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Müller J, Krijgsman O, Tsoi J, Robert L,
Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes
Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to
multiple targeted drugs in melanoma. Nat Commun. 5:57122014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou L, Liu XD, Sun M, Zhang X, German P,
Bai S, Ding Z, Tannir N, Wood CG, Matin SF, et al: Targeting MET
and AXL overcomes resistance to sunitinib therapy in renal cell
carcinoma. Oncogene. 35:2687–2697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller MA, Oudin MJ, Sullivan RJ, Wang SJ,
Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, et al:
Reduced proteolytic shedding of receptor tyrosine kinases is a
post-translational mechanism of kinase inhibitor resistance. Cancer
Discov. 6:382–399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagata K, Nakano T, Arita H, Zong C,
Hanafusa H and Mizuno K: Identification of the product of growth
arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer
receptor tyrosine kinases. J Biol Chem. 271:30022–30027. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varnum BC, Young C, Elliott G, Garcia A,
Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et
al: Axl receptor tyrosine kinase stimulated by the vitamin
K-dependent protein encoded by growth-arrest-specific gene 6.
Nature. 373:623–626. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sasaki T, Knyazev PG, Clout NJ, Cheburkin
Y, Göhring W, Ullrich A, Timpl R and Hohenester E: Structural basis
for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan SB, Peek VL, Ajamie R, Buchanan SG,
Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW, Manro JR, et al:
LY2801653 is an orally bioavailable multi-kinase inhibitor with
potent activity against MET, MST1R, and other oncoproteins, and
displays anti-tumor activities in mouse xenograft models. Invest
New Drugs. 31:833–844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leconet W, Larbouret C, Chardès T, Thomas
G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M,
Bernex F, et al: Preclinical validation of AXL receptor as a target
for antibody-based pancreatic cancer immunotherapy. Oncogene.
33:5405–5414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cerchia L, Esposito CL, Camorani S, Rienzo
A, Stasio L, Insabato L, Affuso A and de Franciscis V: Targeting
Axl with a high-affinity inhibitory aptamer. Mol Ther.
20:2291–2303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paolino M, Choidas A, Wallner S, Pranjic
B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa
JP, et al: The E3 ligase Cbl-b and TAM receptors regulate cancer
metastasis via natural killer cells. Nature. 507:508–512. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenogra tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kariolis MS, Miao YR, Jones DS II, Kapur
S, Mathews II, Giaccia AJ and Cochran JR: An engineered Axl ‘decoy
receptor’ effectively silences the Gas6-Axl signaling axis. Nat
Chem Biol. 10:977–983. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boshuizen J, Koopman LA, Krijgsman O,
Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper
K, Kuilman T, Song JY, et al: Cooperative targeting of melanoma
heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK
inhibitors. Nat Med. 24:203–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen PX, Li QY and Yang Z: Axl and
prostasin are biomarkers for prognosis of ovarian adenocarcinoma.
Ann Diagn Pathol. 17:425–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Darling RJ and Brault PA: Kinetic
exclusion assay technology: Characterization of molecular
interactions. Assay Drug Dev Technol. 2:647–657. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lew ED, Oh J, Burrola PG, Lax I, Zagórska
A, Través PG, Schlessinger J and Lemke G: Differential TAM receptor
ligand phospholipid interactions delimit differential TAM
bioactivities. Elife; 3. 2014
|
|
31
|
Rankin EB, Fuh KC, Castellini L,
Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A,
Lindgren D, et al: Direct regulation of GAS6/AXL signaling by HIF
promotes renal metastasis through SRC and MET. Proc Natl Acad Sci
USA. 111:13373–13378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J,
Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic
target in cancer: Role of Axl in tumor growth, metastasis and
angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
|
